EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative treatments based on the NexACT® technology, announced today that it met with the Food and Drug Administration (FDA) on October 15, 2008 concerning Vitaros® , its topical treatment for erectile dysfunction. The purpose of the meeting was to gain clarification on the major deficiencies cited by the FDA in their July 21, 2008 action letter (the “Action Letter”) and to reach consensus on the necessary actions for addressing these deficiencies for its Vitaros® New Drug Application (NDA).
